Retinoic acid promotes Mycobacterium tuberculosis elimination inducing antimicrobial peptides and cytokines

Peptides ◽  
2021 ◽  
pp. 170580
Author(s):  
Yolanda M. Jacobo-Delgado ◽  
Flor Torres-Juarez ◽  
Jacqueline Alonso-Macias ◽  
Jeny deHaro-Acosta ◽  
Adrián Rodríguez-Carlos ◽  
...  
2019 ◽  
Vol 20 (9) ◽  
pp. 885-892
Author(s):  
Sara Silva ◽  
Nuno Vale

Cationic antimicrobial peptides (CAMPs) can be considered as new potential therapeutic agents for Tuberculosis treatment with a specific amino acid sequence. New studies can be developed in the future to improve the pharmacological properties of CAMPs and also understand possible resistance mechanisms. This review discusses the principal properties of natural and/or synthetic CAMPs, and how these new peptides have a significant specificity for Mycobacterium tuberculosis. Also, we propose some alternative strategies to enhance the therapeutic activity of these CAMPs that include coadministration with nanoparticles and/or classic drugs.


mSphere ◽  
2019 ◽  
Vol 4 (3) ◽  
Author(s):  
Elliot W. Kim ◽  
Avelino De Leon ◽  
Zhichun Jiang ◽  
Roxana A. Radu ◽  
Adrian R. Martineau ◽  
...  

ABSTRACTEpidemiological evidence correlates low serum vitamin A (retinol) levels with increased susceptibility to active tuberculosis (TB); however, retinol is biologically inactive and must be converted into its bioactive form, all-transretinoic acid (ATRA). Given that ATRA triggers a Niemann-Pick type C2 (NPC2)-dependent antimicrobial response againstMycobacterium tuberculosis, we investigated the mechanism by which the immune system converts retinol into ATRA at the site of infection. We demonstrate that granulocyte-macrophage colony-stimulating factor (GM-CSF)-derived dendritic cells (DCs), but not macrophages, express enzymes in the vitamin A metabolic pathway, including aldehyde dehydrogenase 1 family, member a2 (ALDH1A2) and short-chain dehydrogenase/reductase family, member 9 (DHRS9), enzymes capable of the two-step conversion of retinol into ATRA, which is subsequently released from the cell. Additionally, mRNA and protein expression levels of ALDH1A2 and DC marker CD1B were lower in tuberculosis lung tissues than in normal lung. The conditioned medium from DCs cultured with retinol stimulated antimicrobial activity fromM. tuberculosis-infected macrophages, as well as the expression of NPC2 in monocytes, which was blocked by specific inhibitors, including retinoic acid receptor inhibitor (RARi) orN,N-diethylaminobenzaldehyde (DEAB), an ALDH1A2 inhibitor. These results indicate that metabolism of vitamin A by DCs transactivates macrophage antimicrobial responses.IMPORTANCETuberculosis (TB) is the leading cause of death by a single infectious agent worldwide. One factor that contributes to the success of the microbe is the deficiency in immunomodulatory nutrients, such as vitamin A (retinol), which are prevalent in areas where TB is endemic. Clinical trials show that restoration of systemic retinol levels in active TB patients is ineffective in mitigating the disease; however, laboratory studies demonstrate that activation of the vitamin A pathway inMycobacterium tuberculosis-infected macrophages triggers an antimicrobial response. Therefore, the goal of this study was to determine the link between host retinol levels and retinoic acid-mediated antimicrobial responses againstM. tuberculosis. By combining establishedin vitromodels within situstudies of lung tissue from TB patients, this study demonstrates that the innate immune system utilizes transcellular metabolism leading to activation between dendritic cells and macrophages as a means to combat the pathogen.


2019 ◽  
Vol 19 ◽  
pp. 132-135 ◽  
Author(s):  
Sara Silva ◽  
Anabela Santos-Silva ◽  
José Manuel Correia da Costa ◽  
Nuno Vale

2021 ◽  
pp. 1-7
Author(s):  
Jeny de Haro-Acosta ◽  
Yolanda M. Jacobo-Delgado ◽  
Adrian Rodríguez-Carlos ◽  
Flor Torres-Juárez ◽  
Zaida Araujo ◽  
...  

Tuberculosis ◽  
2014 ◽  
Vol 94 (6) ◽  
pp. 678-689 ◽  
Author(s):  
Yun Lan ◽  
Jason T. Lam ◽  
Gilman K.H. Siu ◽  
Wing Cheong Yam ◽  
A. James Mason ◽  
...  

2013 ◽  
Vol 57 (5) ◽  
pp. 2295-2303 ◽  
Author(s):  
Santiago Ramón-García ◽  
Ralf Mikut ◽  
Carol Ng ◽  
Serge Ruden ◽  
Rudolf Volkmer ◽  
...  

ABSTRACTThe lack of effective therapies for treating tuberculosis (TB) is a global health problem. WhileMycobacterium tuberculosisis notoriously resistant to most available antibiotics, we identified synthetic short cationic antimicrobial peptides that were active at low micromolar concentrations (less than 10 μM). These small peptides (averaging 10 amino acids) had remarkably broad spectra of antimicrobial activities against both bacterial and fungal pathogens and an indication of low cytotoxicity. In addition, their antimicrobial activities displayed various degrees of species specificity that were not related to taxonomy. For example,Candida albicansandStaphylococcus aureuswere the best surrogates to predict peptide activity againstM. tuberculosis, whileMycobacterium smegmatiswas a poor surrogate. Principle component analysis of activity spectrum profiles identified unique features associated with activity againstM. tuberculosisthat reflect their distinctive amino acid composition; active peptides were more hydrophobic and cationic, reflecting increased tryptophan with compensating decreases in valine and other uncharged amino acids and increased lysine. These studies provide foundations for development of cationic antimicrobial peptides as potential new therapeutic agents for TB treatment.


2021 ◽  
Vol 14 (4) ◽  
pp. 323
Author(s):  
Gabriel S. Oliveira ◽  
Raquel P. Costa ◽  
Paula Gomes ◽  
Maria Salomé Gomes ◽  
Tânia Silva ◽  
...  

Despite being considered a public health emergency for the last 25 years, tuberculosis (TB) is still one of the deadliest infectious diseases, responsible for over a million deaths every year. The length and toxicity of available treatments and the increasing emergence of multidrug-resistant strains of Mycobacterium tuberculosis renders standard regimens increasingly inefficient and emphasizes the urgency to develop new approaches that are not only cost- and time-effective but also less toxic. Antimicrobial peptides (AMP) are small cationic and amphipathic molecules that play a vital role in the host immune system by acting as a first barrier against invading pathogens. The broad spectrum of properties that peptides possess make them one of the best possible alternatives for a new “post-antibiotic” era. In this context, research into AMP as potential anti-tubercular agents has been driven by the increasing danger revolving around the emergence of extremely-resistant strains, the innate resistance that mycobacteria possess and the low compliance of patients towards the toxic anti-TB treatments. In this review, we will focus on AMP from various sources, such as animal, non-animal and synthetic, with reported inhibitory activity towards Mycobacterium tuberculosis.


2021 ◽  
Author(s):  
Mahmoud Ramadan Elkazzaz ◽  
Amr Ahmed

Abstract Tuberculosis (TB) is a major infectious disease killer globally. It affected 10 million and killed 1.4 million people in 2019 alone. TB is considered a disease caused by a bacterium—Mycobacterium tuberculosis—that usually attacks the lungs, but can attack any part of the body. But TB has a worrisome connection to the novel coronavirus.. Both diseases are airborne and spread when people cough or sneeze. The predicted impact of the COVID-19 pandemic is an additional 190,000 TB deaths in 2020, and it is expected in the next 5 y that there will be up to a 20% increase in the global TB disease burden, stressing the critical need for new safe and effective drugs against Mycobacterium tuberculosis (Mtb). In addition, controlling multidrug-resistant TB (MDR-TB) presents a huge public health challenge. Recently it was showed that hospitalized patients with Tuberculosis are more susceptible to COVID-19 infection and complication. Furthermore, hospitalized patients with MDR-TB are increasingly vulnerable to COVID-19 complications than patients with non-resistant tuberculosis.. For someone with latent TB, contracting COVID-19 could activate the bacterium, potentially leading to an accelerated and more severe form of the disease WHO estimates that these COVID-19 related disruptions in access to TB care could cause an additional half a million TB deaths. Older age, especially >65 years, may be a risk factor for death from COVID-TB, consistent with previous findings indicating that the mortality rate from COVID-19 increases exponentially with age. Thus, the elderly should be the primary focus of both COVID-19 and COVID-TB mitigation efforts due to its much higher mortality risk in that group. COVID-TB patients had a much higher rate of comorbidities than COVID-19 patients At present, evidence suggests that the main transmission route of both COVID-19 and TB is via respiratory droplets, and their main target are the lungs, which can lead to a worse outcome among COVID-19 and TB coinfection patients (aptly abbreviated COVID-TB). As a result, coinfections with common viral and bacterial (COVID-TB) pathogens among hospitalized patients are a severe concern that will likely worsen patient outcomes and pose a real challenge for treating those patients.ConclusionsNew drug discovery could require several years with no guarantee but repurposing established drugs may be useful to treat confection with COVID-19 and Nonresistant Strains of Mycobacterium tuberculosis: or resistant Strains of Mycobacterium tuberculosis . Here we demonstrate that we could utilize the crosstalk among Chicoric Acid, 13-Cis Retinoic Acid, Minocycline and vitamin D as a novel quadrate therapy against Multidrug-resistant TB and COVID-19 coinfection.


Sign in / Sign up

Export Citation Format

Share Document